Multiple myeloma

Mark P. Purdue, Jonathan N. Hofmann, Elizabeth E. Brown, Celine M Vachon

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Multiple myeloma (MM) is the most common malignancy arising from plasma cells, fully differentiated B lymphocytes that produce the immunoglobulin (Ig) heavy- and light-chain molecules comprising antibodies. MM is characterized by an overproduction of clonal plasma cells in the bone marrow and, in most cases, monoclonal secretion of IgG, IgA, or light-chain Ig. Symptoms of end organ damage (hypercalcemia [C], renal failure [R], anemia [A], or bone lesions [B]), herein referred to as CRAB features, were traditionally a necessary criterion for diagnosing MM; however, improvements in treatment and diagnostic techniques have led to updated diagnostic criteria, enabling intervention among patients before the onset of organ damage. Multiple myeloma is an important cause of lymphoid malignancy (LM) mortality in Western populations. In the United States in 2015, MM was estimated to account for approximately one in every five newly diagnosed LMs, and one in every three LM-related deaths.

Original languageEnglish (US)
Title of host publicationSchottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition
PublisherOxford University Press
Pages797-814
Number of pages18
ISBN (Electronic)9780190238667
DOIs
StatePublished - Jan 1 2017

Fingerprint

Multiple Myeloma
Immunoglobulin Light Chains
Plasma Cells
Neoplasms
Immunoglobulin Heavy Chains
Hypercalcemia
Immunoglobulin A
Renal Insufficiency
Anemia
B-Lymphocytes
Immunoglobulin G
Bone Marrow
Bone and Bones
Mortality
Antibodies
Population
Therapeutics

Keywords

  • Bone marrow
  • Hypercalcemia
  • Lymphocyte
  • Multiple myeloma
  • Plasma cell

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Purdue, M. P., Hofmann, J. N., Brown, E. E., & Vachon, C. M. (2017). Multiple myeloma. In Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition (pp. 797-814). Oxford University Press. https://doi.org/10.1093/oso/9780190238667.003.0041

Multiple myeloma. / Purdue, Mark P.; Hofmann, Jonathan N.; Brown, Elizabeth E.; Vachon, Celine M.

Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, 2017. p. 797-814.

Research output: Chapter in Book/Report/Conference proceedingChapter

Purdue, MP, Hofmann, JN, Brown, EE & Vachon, CM 2017, Multiple myeloma. in Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, pp. 797-814. https://doi.org/10.1093/oso/9780190238667.003.0041
Purdue MP, Hofmann JN, Brown EE, Vachon CM. Multiple myeloma. In Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press. 2017. p. 797-814 https://doi.org/10.1093/oso/9780190238667.003.0041
Purdue, Mark P. ; Hofmann, Jonathan N. ; Brown, Elizabeth E. ; Vachon, Celine M. / Multiple myeloma. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, 2017. pp. 797-814
@inbook{8ef3b3efcc1445ccb012c121f7bf5deb,
title = "Multiple myeloma",
abstract = "Multiple myeloma (MM) is the most common malignancy arising from plasma cells, fully differentiated B lymphocytes that produce the immunoglobulin (Ig) heavy- and light-chain molecules comprising antibodies. MM is characterized by an overproduction of clonal plasma cells in the bone marrow and, in most cases, monoclonal secretion of IgG, IgA, or light-chain Ig. Symptoms of end organ damage (hypercalcemia [C], renal failure [R], anemia [A], or bone lesions [B]), herein referred to as CRAB features, were traditionally a necessary criterion for diagnosing MM; however, improvements in treatment and diagnostic techniques have led to updated diagnostic criteria, enabling intervention among patients before the onset of organ damage. Multiple myeloma is an important cause of lymphoid malignancy (LM) mortality in Western populations. In the United States in 2015, MM was estimated to account for approximately one in every five newly diagnosed LMs, and one in every three LM-related deaths.",
keywords = "Bone marrow, Hypercalcemia, Lymphocyte, Multiple myeloma, Plasma cell",
author = "Purdue, {Mark P.} and Hofmann, {Jonathan N.} and Brown, {Elizabeth E.} and Vachon, {Celine M}",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/oso/9780190238667.003.0041",
language = "English (US)",
pages = "797--814",
booktitle = "Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition",
publisher = "Oxford University Press",
address = "United States",

}

TY - CHAP

T1 - Multiple myeloma

AU - Purdue, Mark P.

AU - Hofmann, Jonathan N.

AU - Brown, Elizabeth E.

AU - Vachon, Celine M

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Multiple myeloma (MM) is the most common malignancy arising from plasma cells, fully differentiated B lymphocytes that produce the immunoglobulin (Ig) heavy- and light-chain molecules comprising antibodies. MM is characterized by an overproduction of clonal plasma cells in the bone marrow and, in most cases, monoclonal secretion of IgG, IgA, or light-chain Ig. Symptoms of end organ damage (hypercalcemia [C], renal failure [R], anemia [A], or bone lesions [B]), herein referred to as CRAB features, were traditionally a necessary criterion for diagnosing MM; however, improvements in treatment and diagnostic techniques have led to updated diagnostic criteria, enabling intervention among patients before the onset of organ damage. Multiple myeloma is an important cause of lymphoid malignancy (LM) mortality in Western populations. In the United States in 2015, MM was estimated to account for approximately one in every five newly diagnosed LMs, and one in every three LM-related deaths.

AB - Multiple myeloma (MM) is the most common malignancy arising from plasma cells, fully differentiated B lymphocytes that produce the immunoglobulin (Ig) heavy- and light-chain molecules comprising antibodies. MM is characterized by an overproduction of clonal plasma cells in the bone marrow and, in most cases, monoclonal secretion of IgG, IgA, or light-chain Ig. Symptoms of end organ damage (hypercalcemia [C], renal failure [R], anemia [A], or bone lesions [B]), herein referred to as CRAB features, were traditionally a necessary criterion for diagnosing MM; however, improvements in treatment and diagnostic techniques have led to updated diagnostic criteria, enabling intervention among patients before the onset of organ damage. Multiple myeloma is an important cause of lymphoid malignancy (LM) mortality in Western populations. In the United States in 2015, MM was estimated to account for approximately one in every five newly diagnosed LMs, and one in every three LM-related deaths.

KW - Bone marrow

KW - Hypercalcemia

KW - Lymphocyte

KW - Multiple myeloma

KW - Plasma cell

UR - http://www.scopus.com/inward/record.url?scp=85051051124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051051124&partnerID=8YFLogxK

U2 - 10.1093/oso/9780190238667.003.0041

DO - 10.1093/oso/9780190238667.003.0041

M3 - Chapter

SP - 797

EP - 814

BT - Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition

PB - Oxford University Press

ER -